Efficacy and safety of ADS-5102 (amantadine) extended-release capsules for treating levodopa-induced dyskinesia. (3rd October 2018)

• Record Type: Journal Article
• Authors: Agarwal, Pinky; Ray, Sudeshna; Burdick, Daniel; Griffith, Alida F; Madan, Arina
• Is Part Of: Expert opinion on orphan drugs. Volume 6:Number 10(2018)
• Page Start: 625
• Page End: 634
• Publication Date: 2018-10-03
• Subjects: Amantadine ER/ADS 5102/Gocovri™ -- levodopa induced dyskinesia -- levodopa therapy -- motor complications -- Parkinson`s disease; Orphan drugs -- Periodicals; Rare diseases -- Periodicals; Chemotherapy -- Periodicals; 615.1
• DOI: 10.1080/21678707.2018.1525532
• Languages: English
• ISSNs: 2167-8707

Abstract

ABSTRACT: Introduction : Levodopa induced dyskinesia (LID) is a common motor complication affecting almost 95% of patients after 15 years of levodopa therapy. Dyskinesia in Parkinson`s disease (PD) can be functionally and socially disabling. Amantadine ER/ADS-5102/Gocovri™ is the first and only drug to get FDA approval in August 2017 for treatment of dyskinesias in patients with PD receiving levodopa with or without concomitant dopaminergic medication. Areas covered : This review summarizes the pharmacodynamics, safety and efficacy of Amantadine ER/ADS 5102 in the treatment of LID. Expert opinion : LID is a challenging problem in Parkinson's disease. Although Amantadine IR is effective in treating LID, it is associated with a higher risk of CNS related side effects including sleep disturbances. Pharmacokinetic profile of Amantadine ER formulation consists of a slow rise and a sustained plasma level of approximately twice the level achieved by amantadine IR formulation. Once nighttime dosing of Amantadine ER provides a slow increase in plasma levels during the night and achieves the goal of maximal serum level during the most active hours of morning and mid-day making amantadine ER better tolerated and more efficacious as compared to IR formulations, in PD patients with troublesome dyskinesias.